# Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities

**Authors:** Preeti Moar, Christoffer Granvik, Kim Blom, Erick Bermúdez-Méndez, Florian Gegenfurtner, Julia Wigren Byström, Peter Fjällström, Mikael Åberg, Johan Normark, Karin Loré, Anders F. Johansson, Mattias N. E. Forsell

PMC · DOI: 10.1186/s12916-026-04700-7 · BMC Medicine · 2026-02-24

## TL;DR

This study finds that older adults in Swedish care homes have a higher-than-reported risk of respiratory virus infections, especially RSV, and suggests serological testing can better detect these infections.

## Contribution

The study introduces a scalable serological surveillance system to detect respiratory virus infections in LTCFs, independent of symptoms or healthcare-seeking behavior.

## Key findings

- RSV-specific antibody levels peaked in spring 2022 and again in autumn 2023, indicating significant RSV circulation in LTCFs.
- Estimated RSV burden in LTCFs was much higher than official reports from the Swedish Public Health Agency.
- Higher RSV pre-F antibody levels in autumn 2021 were associated with increased one-year mortality among residents.

## Abstract

Older adults (> 65 years) residing in long-term care facilities (LTCFs) are at elevated risk of severe outcomes from respiratory infections. Infections often remain undetected or present atypically in this population, leading to underdiagnosis. Our study aimed to estimate the respiratory virus infection burden, independent of symptom presentation, among older adults in Swedish LTCFs in the post-pandemic period (2021–2024).

We leveraged capillary blood samples and coupled national registry data from 1622 LTCF residents (median age = 87). A multiplex platform was used to quantify antigen-specific IgG and IgM responses to RSV (pre-/post-F, strain A-specific G-protein), influenza-A (H1N1 and H3N2 HA), influenza-B (HA) and SARS-CoV-2 (spike). Linear mixed-effects models were used to demonstrate the dynamics of antibody levels over time, adjusted for age, sex and comorbidities.

RSV-specific antibody responses peaked in spring 2022 (p < 0.001), suggesting an impact of relaxed COVID-19-related restrictions on RSV exposure at LTCFs. RSV-specific antibodies subsequently declined over time until an increase during autumn 2023 (p < 0.001). Geographic variation in pre-F antibody levels suggested localised RSV outbreaks. The total estimated RSV burden at LTCFs was markedly higher than official reports of the Swedish Public Health Agency. Influenza antibody dynamics reflected seasonal trends and were strongly influenced by annual vaccination. A random forest classifier incorporating serological profiles with demographics, location and comorbidities significantly outperformed a model without serological data (AUC-ROC = 0.67 vs. 0.58), although discriminatory performance remained modest. Higher levels of RSV pre-F antibodies in autumn 2021 were associated with increased one-year mortality in logistic regression (OR = 1.43, p = 0.024). Exploratory survival analysis indicated a trend that elevated levels of RSV pre-F antibodies during low population immunity may confer a transiently elevated early hazard of death, although this did not reach statistical significance (HR = 4.50, p = 0.087).

We observed substantial respiratory virus circulation among older adults in Swedish LTCFs and show that RSV burden is under-reported. The results highlight a need for further research into the role of RSV pre-F antibody levels in preventing severe outcomes, potentially via vaccination of LTCF residents. Our scalable serological surveillance system is a valuable approach to detect respiratory infections in LTCFs, independent of symptom presentation or healthcare-seeking behaviour.

The online version contains supplementary material available at 10.1186/s12916-026-04700-7.

## Linked entities

- **Diseases:** influenza (MONDO:0005812), SARS-CoV-2 (MONDO:0100096), respiratory infections (MONDO:0024355)

## Full-text entities

- **Genes:** S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, FURIN (furin, paired basic amino acid cleaving enzyme) [NCBI Gene 5045] {aka FUR, PACE, PCSK3, SPC1}, ACSBG1 (acyl-CoA synthetase bubblegum family member 1) [NCBI Gene 23205] {aka BG, BG1, BGM, GR-LACS, LPD}
- **Diseases:** pneumonia (MESH:D011014), respiratory (MESH:D012131), PHAS (MESH:C000719203), frailty (MESH:D000073496), Influenza A (MESH:D007251), PC (MESH:D015324), respiratory illness (MESH:D012140), respiratory infection (MESH:D012141), RSV (MESH:D018357), dementia (MESH:D003704), cognitive impairment (MESH:D003072), bronchiolitis (MESH:D001988), Mortality (MESH:D003643), CCI (MESH:C566784), Infection (MESH:D007239), COVID-19 (MESH:D000086382), EMM (MESH:D010437)
- **Chemicals:** imidazole (MESH:C029899), sodium azide (MESH:D019810), salt (MESH:D012492), His (MESH:D006639), Tween-20 (MESH:D011136), PBS (MESH:D007854), COOH (-)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], H1N1 subtype (serotype) [taxon 114727], H3N2 subtype (serotype) [taxon 119210], Orthomyxoviridae (family) [taxon 11308], Respiratory syncytial virus (no rank) [taxon 12814], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** start-stop
- **Cell lines:** Expi293F — Homo sapiens (Human), Transformed cell line (CVCL_D615)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955034/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955034/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955034/full.md

---
Source: https://tomesphere.com/paper/PMC12955034